SCHEMBL25124336

SCHEMBL25124336

O=C(NCc1ncc(F)cc1F)c1cnc(N2CCCC(N3CCCC4(C3)CC4(F)F)CC2)s1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADRA2C P18825 6/20 0.66
▸ ACKR3 P25106 3/20 0.36
▸ MAPK8 P45983 4/20 0.35
▸ ITGB3 P05106 1/20 0.35
▸ ITGA2B P08514 1/20 0.35
▸ HRH3 Q9Y5N1 3/20 0.35
▸ HDAC3 O15379 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC7 Q8WUI4 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC10 Q969S8 1/20 0.33
▸ HDAC11 Q96DB2 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ HDAC9 Q9UKV0 1/20 0.33
▸ HDAC5 Q9UQL6 1/20 0.33
▸ TMPRSS15 P98073 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24183492 0.98 ADRA2C (0.65) ADRA2CACKR3MAPK8ITGB3ITGA2B
SCHEMBL29787279 0.98 ADRA2C (0.65) ADRA2CACKR3MAPK8ITGB3ITGA2B
SCHEMBL30359072 0.98 ADRA2C (0.65) ADRA2CACKR3MAPK8ITGB3ITGA2B
SCHEMBL29787265 0.91 ADRA2C (0.76) ADRA2CACKR3MAPK8ITGB3ITGA2B
SCHEMBL25124266 0.91 ADRA2C (0.76) ADRA2CACKR3MAPK8ITGB3ITGA2B
SCHEMBL24183657 0.90 ADRA2C (0.68) ADRA2CMAPK8ITGB3ITGA2BHRH3
SCHEMBL29787271 0.90 ADRA2C (0.68) ADRA2CMAPK8ITGB3ITGA2BHRH3
SCHEMBL24183576 0.89 ADRA2C (0.79) ADRA2CMAPK8ITGB3ITGA2BHRH3
SCHEMBL24183679 0.87 ADRA2C (0.84) ADRA2CMAPK8TMPRSS15
SCHEMBL24183684 0.86 ADRA2C (0.70) ADRA2CACKR3MAPK8ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2026-02-03 — — US disclosed
CN-120136863-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-06-13 — — CN disclosed
CN-120025328-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-05-23 — — CN disclosed
CN-120025327-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-05-23 — — CN disclosed
CN-114929694-B Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-02-07 — — CN disclosed
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 — — US disclosed
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 — — US disclosed
CN-114929694-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2022-08-19 — — CN disclosed
EP-4021905-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 Bayer Aktiengesellschaft (DE) 2022-07-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 ADRA2C, ADRB3, ADRB2 ADRA2C 1/4885ACKR3 250/4885MAPK8 2755/4885
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 ADRA2C, ADRB2, ADRB3 ADRA2C 1/4885ACKR3 226/4885MAPK8 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback